Home › Prostate Cancer › Massachusetts
Prostate Cancer clinical trials in Massachusetts
68 studies for Prostate Cancer are looking for participants at sites in Massachusetts.
Cities in Massachusetts
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Lahey Clinic, Burlington
- Lahey Clinic Peabody, Peabody
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 29, 2026 · NCT03866382Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence
- Massachusetts General Hospital, Boston
RecruitingPhase 4
Ages 18 and older · Men · Updated Sep 29, 2026 · NCT07569926Precision-Based Genomics in Prostate Cancer
- Dana Farber Cancer Institute, Boston, MA, Boston
RecruitingObservational study
Ages 18 to 120 · Men · Updated Sep 28, 2026 · NCT04706663Barrigel® PPRT (Post-Prostatectomy Radiation Therapy) Trial
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · Men · Updated Sep 28, 2026 · NCT06496256Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
- Harvard Medical School-Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT06801236Reduce HEAT: A Randomized Trial of Wearable Thermal Devices for ADT-Induced Hot Flashes
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07729150Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Dana Farber Mass General Brigham Cancer Care Inc, Boston
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT06800313Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 to 130 · Men · Updated Sep 25, 2026 · NCT07181161A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
- Greater Boston Urology, Plymouth
RecruitingPhase 2
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07832292A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07719361Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2/3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06780670Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Beth Israel Deaconess Med Center, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 to 100 · Men · Updated Sep 22, 2026 · NCT06855277A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Mass General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT07570979CV CARE: CardioVascular Care in PC Patients
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · Men · Updated Sep 22, 2026 · NCT06202820A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07114601A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Research Site, Plymouth
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 18, 2026 · NCT06952803A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Beth Israel Deaconess Medical Center ( Site 0043), Boston
- Dana Farber Cancer Institute ( Site 0012), Boston
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 17, 2026 · NCT06925737A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 15, 2026 · NCT07581184The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 12 and older · All sexes · Updated Sep 15, 2026 · NCT04585750Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT06040125Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, Milford
- and 1 more
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05946213A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Massachusetts General Hospital, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT06465069Serial MRI Scans During Radiation Therapy
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04188535Prostate Active Surveillance Study
- Beth Israel Deaconess Medical Center/Harvard Medical School, Boston
RecruitingObservational study
Ages 21 and older · Men · Updated Sep 2, 2026 · NCT00756665Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- Dana-Farber Cancer Institute at Foxborough, Foxborough
- Dana Farber-Merrimack Valley, Methuen
- Dana-Farber/Brigham and Women's Cancer Center at Milford Regional, Milford
- and 2 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06632977A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide
- Dana Farber Cancer Institute, Boston
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 21, 2026 · NCT06844383FOG-001 in Locally Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05919264Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
- Brigham and Women's Hospital, Boston
RecruitingPhase 2
Ages 40 and older · Men · Updated Aug 17, 2026 · NCT06957691Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- Dana-Farber Cancer Institute / Beth Israel Deaconess Medical Center, Boston
RecruitingPhase 2
Ages 18 and older · Men · Updated Aug 14, 2026 · NCT04812366Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
- Research Site, Boston
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT07336446A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT06067841Distance-Based Exercise to Preserve Function and Prevent Disability
- Dana-Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT07059884RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
- Dana-Farber Cancer Institute at Foxborough, Foxborough
RecruitingPhase 2
Ages 18 and older · Men · Updated Jul 30, 2026 · NCT05765500Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · Men · Updated Jul 29, 2026 · NCT05327465PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
- Dana-Farber Cancer Institute, Boston
RecruitingPhase 3
Ages 18 and older · Men · Updated Jul 22, 2026 · NCT06274047Jump: MR Simulation For Radiation Therapy Master Protocol
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Recruiting
Ages 18 and older · All sexes · Updated Jul 20, 2026 · NCT04545957Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · Men · Updated Jul 2, 2026 · NCT07140900Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
RecruitingObservational studyHealthy volunteers welcome
Ages 19 to 110 · All sexes · Updated Jun 29, 2026 · NCT02012699Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation
- Dana Farber Cancer Institute, Boston
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 8, 2026 · NCT04890613From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.